---
document_datetime: 2023-09-21 17:47:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/avandamet-epar-procedural-steps-taken-authorisation_en.pdf
document_name: avandamet-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3893009
conversion_datetime: 2025-12-20 02:07:07.527826
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company SmithKline Beecham plc submitted on 03 October 2002 an application for Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for Avandamet, through the centralised procedure. After agreement by the CPMP on 25 July 2002, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur Dr. J.F.F. Lekkerkerker Co-Rapporteur Dr. P. Neels Licensing status: A new application was filed in the following countries: USA. The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 21 October 2002. · The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  20 December 2002 · The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  06 January 2003 · During  the  meeting  on  18-20  February  2003  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 20 February 2003 · The company submitted the responses to the CPMP consolidated List of Questions on 14 April 2003. · The  summary  report  of  the  inspection  carried  out  at  the  manufacturing  site  of  the  finished product SB Pharmaco PR Inc, Puerto Rico, between 21-23 May 2003 was issued on 17 June 2003. · The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 21 May 2003. · The  Rapporteur  circulated  an  addendum  to  response  Assessment  Report  on  the  company's responses to the List of Questions to all CPMP members on 13 June 2003. · During the meeting on 24-26 June 2003 the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Avandamet on 26 June 2003. Medicinal product no longer authorised